UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

Notification of Late Filing

 

SEC File Number: 1-16467

 

(Check one):

[  ] Form 10-K [  ] Form 20-F [  ] Form 11-K [X] Form 10-Q
[  ] Form 10-D [  ] Form N-SAR [  ] Form N-CSR  

 

For Period Ended: March 31, 2017

 

[  ] Transition Report on Form 10-K [  ] Transition Report on Form 20-F
[  ] Transition Report on Form 11-K [  ] Transition Report on Form 10-Q
[  ] Transition Report on Form N-SAR  

 

For the Transition Period Ended:

 

Nothing in this form shall be construed to imply that the

Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not applicable.

 

PART I - REGISTRANT INFORMATION

 

RESPIRERX PHARMACEUTICALS INC.

Full Name of Registrant

 

126 Valley Road, Suite C

Address of Principal Executive Office (Street and Number)

 

Glen Rock, New Jersey 07452

(City, State and Zip Code)

 

 

 

 
 

 

PART II - RULES 12B-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) [X]

 

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

RespireRx Pharmaceuticals Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended March 31, 2017 (the “Quarterly Report”) by the May 15, 2017 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements. The recent resignation of the Registrant’s former Chief Financial Officer, as previously reported by the Registrant on a Current Report on Form 8-K file February 23, 2017, contributed to the Registrant’s inability to timely complete its financial statements. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report requires additional time to complete the Quarterly Report. The Registrant intends to file a complete Quarterly Report as soon as practicable within the extension period of five calendar days provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

 

PART IV - OTHER INFORMATION

 

Name and telephone number of person to contact in regard to this notification:

 

Jeff E. Margolis   (201)   444-4947
(Name)   (Area Code)   (Telephone Number)

 

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [X] Yes [  ] No

 

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [  ] Yes [X] No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
 

 

RespireRx Pharmaceuticals Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 15, 2017 RespireRx Pharmaceuticals Inc.
     
  By: /s/ Jeff E. Margolis
    Jeff E. Margolis
    Vice President, Interim Chief Financial Officer,Treasurer and Secretary